Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irofulven - Lantern Pharma

Drug Profile

Irofulven - Lantern Pharma

Alternative Names: 6-HMAF; 6-hydroxymethylacylfulvene; E 7850; HMAF; Irofulven-1; LP 100; MGI 114

Latest Information Update: 08 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Allarity Therapeutics; Dainippon Sumitomo Pharma; Eisai Co Ltd; Lantern Pharma
  • Class Antineoplastics; Cyclopropanes; Indenes; Sesquiterpenes; Small molecules; Spiro compounds
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; RNA polymerase II inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Renal cell carcinoma; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Preclinical Solid tumours
  • Discontinued Cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 08 Jul 2023 Preclinical trials in Solid tumours in USA (unspecified route), prior to June 2023
  • 02 Jun 2023 Pharmacodynamics data from a preclinical trial in Solid tumour presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 15 Mar 2023 Lantern Pharma terminates the phase II trial in Prostate cancer (Hormone refractory, Combination therapy, Second-line therapy or greater, Metastatic disease) in Denmark (IV) due to the reason to allow the focus of LP-100-directed resources on positioning the molecule for development in earlier lines of therapy with potentially larger market opportunities (NCT03643107) (EudraCT2017-003549-72)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top